Hemogenyx Pharmaceuticals PLC (HEMO) · 2026-10-19

Feasibility Study Agreement

Hemogenyx Pharmaceuticals has entered a feasibility study agreement with Nitto Denko to evaluate delivery of its FLT3-CAR mRNA to human T cells. The in-vitro study is expected to take about four months, while its Phase I HG-CT-1 trial remains the company’s principal focus.

Hemogenyx Pharmaceuticals plc (HEMO) · 2026-09-28

Half-year Financial Report

Hemogenyx reported a wider £6.56m H1 pre-tax loss, largely reflecting a £5.54m non-cash option charge, while cash rose to £4.58m after fundraising. Clinical progress continued, but further uncommitted funding is required, creating material going-concern uncertainty.

Hemogenyx Pharmaceuticals plc (HEMO) · 2026-09-03

Exercise of Warrants and Issue of Equity

Hemogenyx Pharmaceuticals plc has received warrant exercise notices for 96,825 new ordinary shares at 180p to 350p, raising £291,665. Admission is expected on or around 8.00 a.m. on 8 September 2026, after which issued shares and voting rights will total 6,896,786.

Hemogenyx Pharmaceuticals plc (HEMO) · 2026-07-29

Collaboration and Company Update

Hemogenyx Pharmaceuticals has signed a Letter of Intent with Lithuania's National Cancer Centre for HG-CT-1 manufacturing and compassionate-use treatment, though substantial preparation is needed before treatment.